23.78  0.62 (2.68%)		05-06 16:00
Open: 23.175 High: 23.8 Volume: 325,001		Pre. Close: 23.16 Low: 22.82 Market Cap: 1,303(M)

Short term
Mid term
Targets	6-month :	28.32	1-year :	33.08
Resists	First :	24.25	Second :	28.32
Pivot price	22.81
Supports	First :	21.48	Second :	19.78
MAs	MA(5) :	22.58	MA(20) :	22.7
	MA(100) :	18.56	MA(250) :	15.31
MACD	MACD :	0.6	Signal :	0.7
%K %D	K(14,3) :	67.6	D(3) :	47.3
RSI	RSI(14): 64.4
52-week	High :	24.25	Low :	7.8

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ BCAX ] has closed below upper band by 21.9%. Bollinger Bands are 2.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	23.81 - 23.88	23.88 - 23.96
Low:	22.61 - 22.69	22.69 - 22.79
Close:	23.63 - 23.76	23.76 - 23.91

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Wed, 06 May 2026
FMR LLC reports 2.10M shares in Bicara Therapeutics (NASDAQ: BCAX) - Stock Titan

Mon, 04 May 2026
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000 - The Motley Fool

Mon, 04 May 2026
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000 - AOL.com

Tue, 28 Apr 2026
Bicara Therapeutics (BCAX) CMO sells 5,500 shares after option exercise - Stock Titan

Tue, 28 Apr 2026
Bicara Therapeutics CMO David Raben sells $125,830 in shares - Investing.com

Wed, 22 Apr 2026
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	66 (M)
Shares Float	42 (M)
Held by Insiders	10.2 (%)
Held by Institutions	93.7 (%)
Shares Short	9,330 (K)
Shares Short P.Month	9,360 (K)

EPS	-2.52
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	7.36
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-20.7 %
Return on Equity (ttm)	-30.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.38
Qtrly Earnings Growth	0 %
Operating Cash Flow	-107 (M)
Levered Free Cash Flow	-66 (M)

PE Ratio	-9.44
PEG Ratio	0
Price to Book value	3.22
Price to Sales	0
Price to Cash Flow	-14.61

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.